Top

Published in:

Open Access 01-12-2023 | Research

A pan-cancer analysis for the oncogenic role of cyclin-dependent kinase inhibitor 1B in human cancers

Authors: Hao Huang, Duoliang Qiu, Zhengyang Zhou, Biaobiao Wu, Lening Shao, Yuwei Pu, Tengfei He, Yongyou Wu, Dawei Cui, Fengyun Zhong

Published in: Discover Oncology | Issue 1/2023

Abstract

Background

Human health and life are threatened by cancer with high morbidity and mortality worldwide. In many experiments, CDKN1B level is associated with cancer risk, Nevertheless, no pan-cancer analysis has been conducted on CDKN1B in human cancers.

Methods

With the help of bioinformatics, a pan-cancer analysis was conducted on the expression levels of CDKN1B in cancer tissues and adjacent tissues from the TCGA, CPTAC and GEO databases. The CDKN1B expression levels in tumor patients was further validated using immunohistochemistry (IHC) and quantitative real-time PCR.

Results

In the study, we first investigated the cancer-related roles of CDKN1B’s in 40 tumors with malignancy. The CDKN1B gene encodes the p27^Kip1 protein, which can block the production cyclin-dependent kinase (CDK), which is obviously related to the function and survival of cancer cells and alters the prognosis of cancer patients. Furthermore, CDKN1B function requires both protein processing and RNA metabolism. Additionally, the elevated expression of the CDKN1B gene and protein was validated in several cancer tissues from the patients.

Conclusions

These results showed that the levels of CDKN1B were considerably different in a number of cancer tissues, offering a potential future target for cancer therapy.

Available only for authorised users

Blum A, Wang P, Zenklusen JC. SnapShot: TCGA-analyzed tumors. Cell. 2018;173(2):530. https://doi.org/10.1016/j.cell.2018.03.059.CrossRefPubMed

Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH, Sherman PM, Holko M, Yefanov A, Lee H, Zhang N, Robertson CL, Serova N, Davis S, Soboleva A. NCBI GEO: archive for functional genomics data sets–update. Nucleic Acids Res. 2013;41(Database issue):D991-995. https://doi.org/10.1093/nar/gks1193.CrossRefPubMed

Liu Y, Wang J, Li L, Qin H, Wei Y, Zhang X, Ren X, Ding W, Shen X, Li G, Lu Z, Zhang D, Qin C, Tao L, Chen X. AC010973.2 promotes cell proliferation and is one of six stemness-related genes that predict overall survival of renal clear cell carcinoma. Sci Rep. 2022;12(1):4272. https://doi.org/10.1038/s41598-022-07070-1.CrossRefPubMedPubMedCentral

Jiang S, Ren X, Liu S, Lu Z, Xu A, Qin C, Wang Z. Integrated analysis of the prognosis-associated RNA-binding protein genes and candidate drugs in renal papillary cell carcinoma. Front Genet. 2021;12:627508. https://doi.org/10.3389/fgene.2021.627508.CrossRefPubMedPubMedCentral

Yu L, Shen H, Ren X, Wang A, Zhu S, Zheng Y, Wang X. Multi-omics analysis reveals the interaction between the complement system and the coagulation cascade in the development of endometriosis. Sci Rep. 2021;11(1):11926. https://doi.org/10.1038/s41598-021-90112-x.CrossRefPubMedPubMedCentral

Tomczak K, Czerwińska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn). 2015;19(1A):A68-77. https://doi.org/10.5114/wo.2014.47136.CrossRefPubMed

Alrezk R, Hannah-Shmouni F, Stratakis CA. MEN4 and CDKN1B mutations: the latest of the MEN syndromes. Endocr Relat Cancer. 2017;24(10):T195–208. https://doi.org/10.1530/ERC-17-0243.CrossRefPubMedPubMedCentral

Viotto D, Russo F, Anania I, Segatto I, Rampioni Vinciguerra GL, Dall’Acqua A, Bomben R, Perin T, Cusan M, Schiappacassi M, Gerratana L, D’Andrea S, Citron F, Vit F, Musco L, Mattevi MC, Mungo G, Nicoloso MS, Sonego M, Massarut S, Sorio R, Barzan L, Franchin G, Giorda G, Lucia E, Sulfaro S, Giacomarra V, Polesel J, Toffolutti F, Canzonieri V, Puglisi F, Gattei V, Vecchione A, Belletti B, Baldassarre G. CDKN1B mutation and copy number variation are associated with tumor aggressiveness in luminal breast cancer. J Pathol. 2021;253(2):234–45. https://doi.org/10.1002/path.5584.CrossRefPubMed

Qin X, Guo H, Wang X, Zhu X, Yan M, Wang X, Xu Q, Shi J, Lu E, Chen W, Zhang J. Exosomal miR-196a derived from cancer-associated fibroblasts confers cisplatin resistance in head and neck cancer through targeting CDKN1B and ING5. Genome Biol. 2019;20(1):12. https://doi.org/10.1186/s13059-018-1604-0.CrossRefPubMedPubMedCentral

10.

Cusan M, Mungo G, De Marco ZM, Segatto I, Belletti B, Baldassarre G. Landscape of CDKN1B mutations in luminal breast cancer and other hormone-driven human tumors. Front Endocrinol (Lausanne). 2018;9:393. https://doi.org/10.3389/fendo.2018.00393.CrossRefPubMed

11.

Feurstein S, Rücker FG, Bullinger L, Hofmann W, Manukjan G, Göhring G, Lehmann U, Heuser M, Ganser A, Döhner K, Schlegelberger B, Steinemann D. Haploinsufficiency of ETV6 and CDKN1B in patients with acute myeloid leukemia and complex karyotype. BMC Genomics. 2014;15(1):784. https://doi.org/10.1186/1471-2164-15-784.CrossRefPubMedPubMedCentral

12.

Bochis OV, Irimie A, Pichler M, Berindan-Neagoe I. The role of Skp2 and its substrate CDKN1B (p27) in colorectal cancer. J Gastrointest Liver Dis. 2015;24(2):225–34. https://doi.org/10.15403/jgld.2014.1121.242.skp2.CrossRef

13.

Razavipour SF, Harikumar KB, Slingerland JM. p27 as a transcriptional regulator: new roles in development and cancer. Cancer Res. 2020;80(17):3451–8. https://doi.org/10.1158/0008-5472.CAN-19-3663.CrossRefPubMed

14.

Ai J, Li J, Su Q, Ma H, Wei Q, Li H, Gao G. rAAV-delivered PTEN therapeutics for prostate cancer. Mol Ther Nucleic Acids. 2021;27:122–32. https://doi.org/10.1016/j.omtn.2021.11.018.CrossRefPubMedPubMedCentral

15.

Choi SH, Barker EC, Gerber KJ, Letterio JJ, Kim BG. Loss of p27^Kip1 leads to expansion of CD4+ effector memory T cells and accelerates colitis-associated colon cancer in mice with a T cell lineage restricted deletion of Smad4. Oncoimmunology. 2020;9(1):1847832. https://doi.org/10.1080/2162402X.2020.1847832.CrossRefPubMedPubMedCentral

16.

Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, Li B, Liu XS. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48(W1):W509–14. https://doi.org/10.1093/nar/gkaa407.CrossRefPubMedPubMedCentral

17.

Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47(W1):W556–60. https://doi.org/10.1093/nar/gkz430.CrossRefPubMedPubMedCentral

18.

Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK, Varambally S. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19(8):649–58. https://doi.org/10.1016/j.neo.2017.05.002.CrossRefPubMedPubMedCentral

19.

Wu P, Heins ZJ, Muller JT, Katsnelson L, de Bruijn I, Abeshouse AA, Schultz N, Fenyö D, Gao J. Integration and analysis of CPTAC proteomics data in the context of cancer genomics in the cBioPortal. Mol Cell Proteomics. 2019;18(9):1893–8. https://doi.org/10.1074/mcp.TIR119.001673.CrossRefPubMedPubMedCentral

20.

Chen F, Chandrashekar DS, Varambally S, Creighton CJ. Pan-cancer molecular subtypes revealed by mass-spectrometry-based proteomic characterization of more than 500 human cancers. Nat Commun. 2019;10(1):5679. https://doi.org/10.1038/s41467-019-13528-0.CrossRefPubMedPubMedCentral

21.

Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–4. https://doi.org/10.1158/2159-8290.CD-12-0095.CrossRefPubMed

22.

Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1. https://doi.org/10.1126/scisignal.2004088.CrossRefPubMedPubMedCentral

23.

Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, Santos A, Doncheva NT, Roth A, Bork P, Jensen LJ, von Mering C. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res. 2017;45(D1):D362–8. https://doi.org/10.1093/nar/gkw937.CrossRefPubMed

24.

Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork P, Jensen LJ, Mering CV. STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607–13. https://doi.org/10.1093/nar/gky1131.CrossRefPubMed

25.

Jia A, Xu L, Wang Y. Venn diagrams in bioinformatics. Brief Bioinform. 2021;22(5):bbab108. https://doi.org/10.1093/bib/bbab108.CrossRefPubMed

26.

Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol. 2003;4(5):P3.CrossRefPubMed

27.

Cao H, Zhao J, Chen Z, Sun W, Ruan K, Zhou J, Zhou J. Loss of LIMCH1 predicts poor prognosis in patients with surgically resected lung adenocarcinoma: a study based on immunohistochemical analysis and bioinformatics. J Cancer. 2021;12(1):181–9. https://doi.org/10.7150/jca.47883.CrossRefPubMedPubMedCentral

28.

Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017;45(D1):D353–61. https://doi.org/10.1093/nar/gkw1092.CrossRefPubMed

29.

Zhang C, Peng L, Zhang Y, Liu Z, Li W, Chen S, Li G. The identification of key genes and pathways in hepatocellular carcinoma by bioinformatics analysis of high-throughput data. Med Oncol. 2017;34(6):101. https://doi.org/10.1007/s12032-017-0963-9.CrossRefPubMedPubMedCentral

30.

Xie Y, Shi X, Sheng K, Han G, Li W, Zhao Q, Jiang B, Feng J, Li J, Gu Y. PI3K/Akt signaling transduction pathway, erythropoiesis and glycolysis in hypoxia (Review). Mol Med Rep. 2019;19(2):783–91. https://doi.org/10.3892/mmr.2018.9713.CrossRefPubMed

31.

Lin K, Qiang W, Zhu M, Ding Y, Shi Q, Chen X, Zsiros E, Wang K, Yang X, Kurita T, Xu EY. Mammalian Pum1 and Pum2 control body size via translational regulation of the cell cycle inhibitor Cdkn1b. Cell Rep. 2019;26(9):2434-2450.e6. https://doi.org/10.1016/j.celrep.2019.01.111.CrossRefPubMedPubMedCentral

32.

Ren C, Yu M, Zhang Y, Fan M, Chang F, Xing L, Liu Y, Wang Y, Qi X, Liu C, Zhang Y, Cui H, Li K, Gao L, Pan Q, Wang X, Gao Y. Avian leukosis virus subgroup J promotes cell proliferation and cell cycle progression through miR-221 by targeting CDKN1B. Virology. 2018;519:121–30. https://doi.org/10.1016/j.virol.2018.04.008.CrossRefPubMed

33.

Hu XH, Zhao ZX, Dai J, Geng DC, Xu YZ. MicroRNA-221 regulates osteosarcoma cell proliferation, apoptosis, migration, and invasion by targeting CDKN1B/p27. J Cell Biochem. 2019;120(3):4665–74. https://doi.org/10.1002/jcb.27755.CrossRefPubMed

34.

Ma S, Chen X, Tan Q, Li D, Dai S, Wu S, Yu Y, Zang G, Tang Z. An engineered novel lentivector specifically transducing dendritic cells and eliciting robust HBV-specific CTL response by upregulating autophagy in T cells. Cell Cycle. 2018;17(10):1220–34. https://doi.org/10.1080/15384101.2018.1471312.CrossRefPubMedPubMedCentral

35.

Biffi G, Tuveson DA. Diversity and biology of cancer-associated fibroblasts. Physiol Rev. 2021;101(1):147–76. https://doi.org/10.1152/physrev.00048.2019.CrossRefPubMed

36.

Wu D, Yin Z, Ji Y, Li L, Li Y, Meng F, Ren X, Xu M. Identification of novel autophagy-related lncRNAs associated with a poor prognosis of colon adenocarcinoma through bioinformatics analysis. Sci Rep. 2021;11(1):8069. https://doi.org/10.1038/s41598-021-87540-0.CrossRefPubMedPubMedCentral

37.

Moiola C, De Luca P, Gardner K, Vazquez E, De Siervi A. Cyclin T1 overexpression induces malignant transformation and tumor growth. Cell Cycle. 2010;9(15):3119–26. https://doi.org/10.4161/cc.9.15.12526.CrossRefPubMedPubMedCentral

38.

Gupta P, Zhao H, Hoang B, Schwartz EL. Targeting the untargetable: RB1-deficient tumours are vulnerable to Skp2 ubiquitin ligase inhibition. Br J Cancer. 2022;127(6):969–75. https://doi.org/10.1038/s41416-022-01898-0.CrossRefPubMedPubMedCentral

39.

Gao LF, Jia S, Zhang QM, Xia YF, Li CJ, Li YH. MicroRNA-802 promotes the progression of osteosarcoma through targeting p27 and activating PI3K/AKT pathway. Clin Transl Oncol. 2022;24(2):266–75. https://doi.org/10.1007/s12094-021-02683-w.CrossRefPubMed

40.

Hou W, Kaczorowski A, Lantwin P, Kippenberger M, Schütz V, Franke D, Dieffenbacher SC, Hohenfellner M, Duensing S. Microenvironment-derived FGF-2 stimulates renal cell carcinoma cell proliferation through modulation of p27^Kip1: implications for spatial niche formation and functional intratumoral heterogeneity. Pathobiology. 2020;87(2):114–24. https://doi.org/10.1159/000506709.CrossRefPubMed

Title: A pan-cancer analysis for the oncogenic role of cyclin-dependent kinase inhibitor 1B in human cancers
Authors: Hao Huang
Duoliang Qiu
Zhengyang Zhou
Biaobiao Wu
Lening Shao
Yuwei Pu
Tengfei He
Yongyou Wu
Dawei Cui
Fengyun Zhong
Publication date: 01-12-2023
Publisher: Springer US
Published in: Discover Oncology / Issue 1/2023
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI: https://doi.org/10.1007/s12672-023-00746-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2023

The role of RNA modification in urological cancers: mechanisms and clinical potential

Association between vascular ultrasound features and DNA sequencing in breast cancer: a preliminary study

Natural killer cells modified with a Gpc3 aptamer enhance adoptive immunotherapy for hepatocellular carcinoma

Role of exosome-mediated molecules SNORD91A and SLC40A1 in M2 macrophage polarization and prognosis of ESCC

Down-regulation of DPP4 by TGFβ1/miR29a-3p inhibited proliferation and promoted migration of ovarian cancer cells

High pre-chemoradiotherapy pan-immune-inflammation value levels predict worse outcomes in patients with stage IIIB/C non-small-cell lung cancer

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials